within Pharmacolibrary.Drugs.ATC.S;

model S01EA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Dipivefrine (dipivefrin) is a prodrug of epinephrine used as an ophthalmic solution (eye drops) for the treatment of open-angle glaucoma and ocular hypertension. It is hydrolyzed to epinephrine in the eye, reducing intraocular pressure. It is approved for ophthalmic use but has largely been replaced by more modern therapies.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ocular administration in adults. No direct human systemic pharmacokinetic model data available, but local ocular conversion and effect characteristics are reported.</p><h4>References</h4><ol><li>I Goldberg, A E Kolker, M A Kass, B Becker,Dipivefrin: current concepts.,Australian journal of ophthalmology,1980<a href='https://pubmed.ncbi.nlm.nih.gov/7004425/'>https://pubmed.ncbi.nlm.nih.gov/7004425/</a></li><li>T JÃ¤rvinen, J Rautio, R Niemi,[Prodrugs].,Duodecim; laaketieteellinen aikakauskirja,1997<a href='https://pubmed.ncbi.nlm.nih.gov/10892164/'>https://pubmed.ncbi.nlm.nih.gov/10892164/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01EA02;
